Radiotherapy and increased risk of second primary cancers in breast cancer survivors: An epidemiological and large cohort study

IF 5.7 2区 医学 Q1 OBSTETRICS & GYNECOLOGY Breast Pub Date : 2024-10-19 DOI:10.1016/j.breast.2024.103824
Niuniu Hou , Zhe Wang , Yuwei Ling , Guangdong Hou , Bo Zhang , Xue Zhang , Mei Shi , Zhuling Chu , Yaoling Wang , Jun Hu , Chong Chen , Rui Ling
{"title":"Radiotherapy and increased risk of second primary cancers in breast cancer survivors: An epidemiological and large cohort study","authors":"Niuniu Hou ,&nbsp;Zhe Wang ,&nbsp;Yuwei Ling ,&nbsp;Guangdong Hou ,&nbsp;Bo Zhang ,&nbsp;Xue Zhang ,&nbsp;Mei Shi ,&nbsp;Zhuling Chu ,&nbsp;Yaoling Wang ,&nbsp;Jun Hu ,&nbsp;Chong Chen ,&nbsp;Rui Ling","doi":"10.1016/j.breast.2024.103824","DOIUrl":null,"url":null,"abstract":"<div><h3>Background</h3><div>Radiotherapy (RT) for breast cancer (BC) may raise the risk of second primary cancers (SPCs), a relationship inadequately studied.</div></div><div><h3>Methods</h3><div>We analyzed 248268 female BC patients from 9 SEER registries, 1988–2018, identifying SPCs &gt;5 years after initial treatment, comparing SPC risks between RT and non-RT cohorts using Fine-Gray and Poisson regressions.</div></div><div><h3>Results</h3><div>Of all participants, 55.4 % received surgery and RT. The RT group had a higher SPC incidence, with excess incidence significantly dropped from 6.9 % in 1990 to 0.2 % in 2012. The 30-year SPC incidence was 24.69 % in the RT cohort and 18.11 % in the NRT cohort. RT increased the risk of SPCs(HR, 1.29 [95%CI,1.26–1.33]; P &lt; 0.001), BC(HR, 1.58[1.52–1.64]; P &lt; 0.001), cancer of respiratory system(HR, 1.21[1.13–1.30]; P = 0.013), skin cancer(HR, 1.26[1.10–1.44]; P &lt; 0.001), leukemia(HR, 1.30[1.11–1.54]; P = 0.001), soft tissue cancer(HR, 1.78[1.34–2.37]; P &lt; 0.001), and eye &amp; orbit cancer(HR, 2.21[1.02–4.80]; P = 0.044), except for reducing the risk of multiple myeloma (HR 0.76). Notably, RT-related risks(RR) for BC declined with increasing age and the year of BC diagnosed, increased with longer latency, but the dynamic RR for cancer of respiratory system presented the almost opposite trends. The RT cohort had higher standardized incidence ratios for SPCs compared to both the NRT cohort and the general population overall. Although 15-year overall survival for SPCs was similar between RT and NRT cohorts, SPC presence significantly lowered 30-year survival from 35.64 % to 23.90 %.</div></div><div><h3>Conclusions</h3><div>RT might increase susceptibility to SPC in breast, respiratory system, skin, soft tissue, eye and orbit, and leukemia in BC survivors. Efforts should be made to timely diagnose SPCs based on their specific patterns to improve patient's quality of life.</div></div>","PeriodicalId":9093,"journal":{"name":"Breast","volume":"78 ","pages":"Article 103824"},"PeriodicalIF":5.7000,"publicationDate":"2024-10-19","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Breast","FirstCategoryId":"3","ListUrlMain":"https://www.sciencedirect.com/science/article/pii/S0960977624001553","RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q1","JCRName":"OBSTETRICS & GYNECOLOGY","Score":null,"Total":0}
引用次数: 0

Abstract

Background

Radiotherapy (RT) for breast cancer (BC) may raise the risk of second primary cancers (SPCs), a relationship inadequately studied.

Methods

We analyzed 248268 female BC patients from 9 SEER registries, 1988–2018, identifying SPCs >5 years after initial treatment, comparing SPC risks between RT and non-RT cohorts using Fine-Gray and Poisson regressions.

Results

Of all participants, 55.4 % received surgery and RT. The RT group had a higher SPC incidence, with excess incidence significantly dropped from 6.9 % in 1990 to 0.2 % in 2012. The 30-year SPC incidence was 24.69 % in the RT cohort and 18.11 % in the NRT cohort. RT increased the risk of SPCs(HR, 1.29 [95%CI,1.26–1.33]; P < 0.001), BC(HR, 1.58[1.52–1.64]; P < 0.001), cancer of respiratory system(HR, 1.21[1.13–1.30]; P = 0.013), skin cancer(HR, 1.26[1.10–1.44]; P < 0.001), leukemia(HR, 1.30[1.11–1.54]; P = 0.001), soft tissue cancer(HR, 1.78[1.34–2.37]; P < 0.001), and eye & orbit cancer(HR, 2.21[1.02–4.80]; P = 0.044), except for reducing the risk of multiple myeloma (HR 0.76). Notably, RT-related risks(RR) for BC declined with increasing age and the year of BC diagnosed, increased with longer latency, but the dynamic RR for cancer of respiratory system presented the almost opposite trends. The RT cohort had higher standardized incidence ratios for SPCs compared to both the NRT cohort and the general population overall. Although 15-year overall survival for SPCs was similar between RT and NRT cohorts, SPC presence significantly lowered 30-year survival from 35.64 % to 23.90 %.

Conclusions

RT might increase susceptibility to SPC in breast, respiratory system, skin, soft tissue, eye and orbit, and leukemia in BC survivors. Efforts should be made to timely diagnose SPCs based on their specific patterns to improve patient's quality of life.
查看原文
分享 分享
微信好友 朋友圈 QQ好友 复制链接
本刊更多论文
放疗与乳腺癌幸存者罹患第二原发性癌症风险的增加:一项流行病学大型队列研究。
背景:乳腺癌(BC)放疗(RT)可能会增加罹患第二原发性癌症(SPC)的风险,但对两者之间的关系研究不足:我们分析了1988-2018年9个SEER登记处的248268名女性BC患者,确定了初次治疗后5年以上的SPC,并使用Fine-Gray和泊松回归比较了RT和非RT队列的SPC风险:在所有参与者中,55.4%接受了手术和RT治疗。RT组的SPC发生率较高,超额发生率从1990年的6.9%显著下降到2012年的0.2%。RT组的30年SPC发病率为24.69%,NRT组为18.11%。RT 增加了 SPC 的风险(HR,1.29 [95%CI,1.26-1.33];P 结论:RT可能会增加BC幸存者乳腺、呼吸系统、皮肤、软组织、眼眶和白血病的SPC易感性。应努力根据 SPC 的具体模式及时诊断 SPC,以提高患者的生活质量。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 去求助
来源期刊
Breast
Breast 医学-妇产科学
CiteScore
8.70
自引率
2.60%
发文量
165
审稿时长
59 days
期刊介绍: The Breast is an international, multidisciplinary journal for researchers and clinicians, which focuses on translational and clinical research for the advancement of breast cancer prevention, diagnosis and treatment of all stages.
期刊最新文献
Treatment of oligometastatic breast cancer: The role of patient selection. Current and future burden of breast cancer in Asia: A GLOBOCAN data analysis for 2022 and 2050 Olaparib monotherapy in advanced triple-negative breast cancer patients with homologous recombination deficiency and without germline mutations in BRCA1/2: The NOBROLA phase 2 study Preoperative reference values for breast cancer patients using the BREAST-Q The “lows”: Update on ER-low and HER2-low breast cancer
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
现在去查看 取消
×
提示
确定
0
微信
客服QQ
Book学术公众号 扫码关注我们
反馈
×
意见反馈
请填写您的意见或建议
请填写您的手机或邮箱
已复制链接
已复制链接
快去分享给好友吧!
我知道了
×
扫码分享
扫码分享
Book学术官方微信
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术
文献互助 智能选刊 最新文献 互助须知 联系我们:info@booksci.cn
Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。
Copyright © 2023 Book学术 All rights reserved.
ghs 京公网安备 11010802042870号 京ICP备2023020795号-1